EOC Pharma confirms plans to advance Efti in China for MBC
Filed with ASX · · 2 pages · English
Story so far
Earlier from Immutep
- Immutep AIPAC Ph2b Clinical Results & Update Webcast Slides
- Immutep reports supportive efficacy data from AIPAC study
- Immutep receives 2nd IND approval for efti from US FDA
- Immutep reports positive TACTI-002 data
- Immutep Activities Report
Later from Immutep
- Immutep presents TACTI-002 data at AACR Virtual Meeting
- Immutep advances its LAG-3 agonist for autoimmune diseases
- Immutep March Quarterly Activities Report & Appendix 4C
- Enrollment completed for the INSIGHT-004 Study
- Immutep Reports Positive Phase II TACTI-002 Data
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep